Cargando…

Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution

BACKGROUND: Focal treatment for prostate cancer (PCa) is a hybrid approach combining ablative treatment of the involved prostate gland and continued active surveillance (AS) of the unaffected gland. Low dose-rate (LDR) brachytherapy can be used as a lesion-targeted focal therapy, however, further st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Elliot, Smyth, Lloyd M. L., O’Sullivan, Richard, Ryan, Andrew, Lawrentschuk, Nathan, Grummet, Jeremy, See, Andrew W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511546/ https://www.ncbi.nlm.nih.gov/pubmed/34733655 http://dx.doi.org/10.21037/tau-21-508

Ejemplares similares

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?
por: Ong, Sean, et al.
Publicado: (2022)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes
por: Chao, Michael, et al.
Publicado: (2018)

Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol
por: Fernandez Ots, Ana, et al.
Publicado: (2016)

Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study
por: Mahdavi, S. Sara, et al.
Publicado: (2017)

Definitions of “Cure” After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
por: Boehle, Andreas, et al.
Publicado: (2022)

Active surveillance and focal therapy for low-intermediate risk prostate cancer
por: Klotz, Laurence
Publicado: (2015)

Efficacy of focal high-dose-rate brachytherapy in the treatment of patients diagnosed with low or favourable intermediate-risk prostate cancer—a protocol for a randomised controlled trial
por: Jonušas, Justinas, et al.
Publicado: (2023)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
por: Okamoto, Keisei, et al.
Publicado: (2020)

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
por: Kunogi, Hiroaki, et al.
Publicado: (2016)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Krishnananthan, Nishanth, et al.
Publicado: (2016)

Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience
por: Barnes, Justin M., et al.
Publicado: (2019)

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients
por: Woo, Henry H, et al.
Publicado: (2017)

(68)Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial
por: Bowden, Patrick, et al.
Publicado: (2021)

Low-/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team experience
por: Villalba, Silvia Rodríguez, et al.
Publicado: (2021)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
por: Nakamura, Satoshi, et al.
Publicado: (2016)

Do androgen deprivation and the biologically equivalent dose matter in low‐dose‐rate brachytherapy for intermediate‐risk prostate cancer?
por: Tabata, Ryuji, et al.
Publicado: (2016)

Australian patterns of prostate cancer care: Are they evolving?
por: Lo, Jonathon, et al.
Publicado: (2016)

Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?
por: Safdieh, Joseph, et al.
Publicado: (2016)

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
por: Johansson, Bengt, et al.
Publicado: (2021)

Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer
por: Guinot, Jose Luis, et al.
Publicado: (2022)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Disabling chronic low back pain as an iatrogenic disorder: a qualitative study in Aboriginal Australians
por: Lin, Ivan B, et al.
Publicado: (2013)

Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial
por: See, Andrew W., et al.
Publicado: (2022)

Comparative Effectiveness of Radiotherapy versus Focal Laser Ablation in Patients with Low and Intermediate Risk Localized Prostate Cancer
por: Zhou, Xianghong, et al.
Publicado: (2020)

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
por: Khanolkar, Rutvij A., et al.
Publicado: (2021)

Using theory to improve low back pain care in Australian Aboriginal primary care: a mixed method single cohort pilot study
por: Lin, Ivan B., et al.
Publicado: (2016)

Significant impact of transperineal template biopsy of the prostate at a single tertiary institution
por: Huang, Sean, et al.
Publicado: (2015)

Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
por: Cordoba, A., et al.
Publicado: (2016)

Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel space
por: Chao, Michael, et al.
Publicado: (2019)

Risk factors for infection following prostate biopsy - a case control study
por: Anderson, Elliot, et al.
Publicado: (2015)

Radiotherapy and Brachytherapy : Proceedings of the NATO Advanced Study Institute on Physics of Modern Radiotherapy & Brachytherapy
por: Caner, Alessandra, et al.
Publicado: (2009)

The direct prognosis comparison of (125)I low-dose-rate brachytherapy versus laparoscopic radical prostatectomy for patients with intermediate-risk prostate cancer
por: Liang, Zhen, et al.
Publicado: (2023)

Feasibility and early toxicity of focal or partial brachytherapy in prostate cancer patients
por: Kim, Tae Heon, et al.
Publicado: (2020)

Low-frequency intermediate penetrance variants in the ROCK1 gene predispose to Tetralogy of Fallot
por: Palomino Doza, Julian, et al.
Publicado: (2013)

Erratum to: Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients)
por: Cordoba, Abel, et al.
Publicado: (2016)

Clinical outcomes of iodine-125 low-dose-rate brachytherapy for localized prostate cancer: a single-institution review in Japan
por: Nakiri, Makoto, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
por: Jeong, Bae-Kwon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ndq88osas1k1caege8flah06uc